This proposal aims to genetically determine the involvement of excess N-methyl-D-aspartate receptor (NMDAR) activity in the pathogenesis of early cognitive deficits of Down syndrome. Oligomeric Ap peptides are known to be generated very early in Down syndrome because of the extra copy of the APP (amyloid precursor protein) gene on chromosome 21 (the trisomic chromosome in humans with Down syndrome). We propose that the early synaptic damage that is known to occur in Down syndrome brains may, at least in part, be due to excessive levels of Ap peptides. One possible mechanism by which excessive AB may cause synaptic loss and neuronal injury is via NMDAR activation, since it is known that AB increases glutamate release from astrocytes. NR3A subunits inhibit NMDAR activity and act as neuroprotective molecules that mitigate neuronal injury caused by various experimental paradigms. Our recent data indicate that AB induces greater synaptic injury to NR3A-knockout (KO) neurons compared to wild-type (WT) neurons. In addition, we have identified a large gene family that we named takusan (meaning """"""""many"""""""" in Japanese), which regulates synaptic activity. Based on the properties of takusan proteins, we postulated that this molecule might also protect synapses. In this proposal, we will genetically cross Ts65Dn mice, a mouse model of Down syndrome, with mice mutant in NR3A or takusan genes. We will then evaluate the consequences of these crosses for early neurological and cognitive deficits, as well as dendritic spine loss and electrophysiological abnormalities that have been observed in Ts65Dn mice. These experiments will determine whether NR3A and/or takusan play mechanistic roles in possible protection from the synaptic damage that occurs in Down syndrome.
Our Specific Aims are as follows: (1) To determine the potential ill effect of NRSA KO of the NMDAR in the pathogenesis of cognitive deficits in Down syndrome. (2) To determine the potential beneficial effect of expression of the NR3A subunit of the NMDAR on the pathogenesis of cognitive deficits in Down syndrome. (3) To identify the effect of takusan in protecting from AB-induced synaptic spine loss.
The incidence of Down syndrome in the US population is rising as maternal age increases, in spite of improved screenings. The quality of life for those with Down syndrome is most affected by intellectual and neurological disabilities. This proposal aims to understand the pathogenesis of early cognitive deficits in Down syndrome, so that rational and effective therapies can be developed.
|Tu, Shichun; Akhtar, Mohd Waseem; Escorihuela, Rosa Maria et al. (2017) NitroSynapsin therapy for a mouse MEF2C haploinsufficiency model of human autism. Nat Commun 8:1488|
|Chen, Shanyan; Cui, Jiankun; Jiang, Tao et al. (2017) Gelatinase activity imaged by activatable cell-penetrating peptides in cell-based and in vivo models of stroke. J Cereb Blood Flow Metab 37:188-200|
|Nagar, Saumya; Trudler, Dorit; McKercher, Scott R et al. (2017) Molecular Pathway to Protection From Age-Dependent Photoreceptor Degeneration in Mef2 Deficiency. Invest Ophthalmol Vis Sci 58:3741-3749|
|Nakamura, Tomohiro; Lipton, Stuart A (2017) 'SNO'-Storms Compromise Protein Activity and Mitochondrial Metabolism in Neurodegenerative Disorders. Trends Endocrinol Metab 28:879-892|
|Nagar, Saumya; Noveral, Sarah M; Trudler, Dorit et al. (2017) MEF2D haploinsufficiency downregulates the NRF2 pathway and renders photoreceptors susceptible to light-induced oxidative stress. Proc Natl Acad Sci U S A 114:E4048-E4056|
|Mann, Aman P; Scodeller, Pablo; Hussain, Sazid et al. (2017) Identification of a peptide recognizing cerebrovascular changes in mouse models of Alzheimer's disease. Nat Commun 8:1403|
|Satoh, Takumi; Lipton, Stuart (2017) Recent advances in understanding NRF2 as a druggable target: development of pro-electrophilic and non-covalent NRF2 activators to overcome systemic side effects of electrophilic drugs like dimethyl fumarate. F1000Res 6:2138|
|Nakamura, Tomohiro; Lipton, Stuart A (2016) Nitrosative Stress in the Nervous System: Guidelines for Designing Experimental Strategies to Study Protein S-Nitrosylation. Neurochem Res 41:510-4|
|Nakamura, Tomohiro; Lipton, Stuart A (2016) Protein S-Nitrosylation as a Therapeutic Target for Neurodegenerative Diseases. Trends Pharmacol Sci 37:73-84|
|Lipton, Stuart A; Rezaie, Tayebeh; Nutter, Anthony et al. (2016) Therapeutic advantage of pro-electrophilic drugs to activate the Nrf2/ARE pathway in Alzheimer's disease models. Cell Death Dis 7:e2499|
Showing the most recent 10 out of 173 publications